Financials in USD. Standardized financial statements.
A compact view of how Shenzhen Hepalink Pharmaceutical Group Co., Ltd. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $5.48B | $5.28B | $5.45B | $7.16B | $6.37B | $5.33B | $4.62B | $4.81B | $2.67B | $2.26B |
| Revenue Growth? | +3.8% | -3.0% | -23.9% | +12.5% | +19.4% | +15.3% | -4.0% | +80.3% | +18.1% | 0.0% |
| Cost of Revenue? | $3.74B | $3.52B | $4.50B | $4.83B | $4.33B | $3.24B | $2.90B | $2.88B | $2.03B | $1.54B |
| Gross Profit? | $1.74B | $1.76B | $944.92M | $2.33B | $2.03B | $2.09B | $1.73B | $1.93B | $640.01M | $723.34M |
| Gross Margin? | +31.8% | +33.3% | +17.4% | +32.6% | +31.9% | +39.2% | +37.3% | +40.1% | +24.0% | +32.0% |
| Operating Expenses? | $1.11B | $1.01B | $1.81B | $1.21B | $1.07B | $960.98M | $896.50M | $845.39M | $450.61M | $457.11M |
| Operating Income? | $635.97M | $741.31M | -$860.91M | $828.62M | $227.47M | $1.33B | $1.31B | $721.15M | -$7.40M | $435.61M |
| EBITDA? | $846.59M | $1.20B | -$320.45M | $1.38B | $731.27M | $1.88B | $1.83B | $1.12B | $348.64M | $391.82M |
| Income Before Tax | $402.24M | $726.23M | -$928.33M | $829.85M | $222.26M | $1.33B | $1.31B | $730.85M | $4.50M | $474.94M |
| Income Tax Expense | $59.60M | $101.31M | -$126.17M | $115.16M | -$11.12M | $306.20M | $271.38M | $138.66M | -$113.68M | $88.82M |
| Net Income? | $349.49M | $646.74M | -$783.26M | $727.43M | $240.79M | $1.02B | $1.06B | $616.19M | $131.33M | $396.89M |
| EPS? | $0.24 | $0.44 | $-0.53 | $0.50 | $0.16 | $0.76 | $0.85 | $0.49 | $0.11 | $0.32 |
| Diluted EPS? | $0.24 | $0.44 | $-0.53 | $0.50 | $0.16 | $0.76 | $0.85 | $0.49 | $0.11 | $0.32 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality